Events All Events

Harvard's Office of Technology Development and LabCentral invite you to the latest event in the Guppy Tank series, where Harvard life-science innovators will pitch their early-stage concepts to a panel of entrepreneurs and investors for constructive, in-depth feedback.

Please join us on Tuesday, June 9 from 4:00 to 6:00 p.m. at LabCentral to hear the presentation, learn from experts on startup formation, and participate in giving audience feedback. The event is accompanied by a reception with food and drinks. All are welcome!

Dr. Mitragotri and Dr. Bisharyan welcome constructive feedback from the Guppy Tank panelists, and from the audience, on the commercialization strategy for this innovation.

Register Here

Presented by:

Samir Mitragotri, 

Hiller Professor of Bioengineering and Hansjörg Wyss Professor of Biologically Inspired Engineering,
Harvard John A. Paulson School of Engineering and Applied Sciences

Yelena Bisharyan, 

CEO, Trillion Bio

The Panel:

Luca Giani, Senior Principal at Alumni Ventures

Michael Gladstone, Partner at Atlas Ventures

More panelists to be announced soon!

About the Project:

Injectable biologics represent a major therapeutic category for diseases such as cancer, autoimmune disorders, and infections, with the market projected to exceed $1 trillion by 2030. While these therapies span peptides, nucleic acids, and proteins, most particularly monoclonal antibodies are administered intravenously, driving up costs and limiting patient convenience.

Currently, subcutaneous administration of antibodies is limited by low and variable bioavailability, on average ~60%, necessitating higher drug doses. This, in turn, increases manufacturing costs and requires formulations at high concentrations. The use of such high-concentration formulations is further constrained by the limited solubility and stability of high–molecular-weight proteins, forcing the industry to either to use enzymes to degrade subcutaneous tissue to accommodate large volumes or use suspensions to increase antibody loading in the formulation.

Trillion Bio overcomes these challenges using the Ionic Liquid technology, which enhances bioavailability from the subcutaneous space to near-complete levels, thereby reducing dose requirements and increasing predictability. In addition, Trillion Bio’s ionic liquids improve the solubility and stability of antibodies in a solution format, reaching concentrations that were previously unattainable. This allows dosing of therapeutic amounts of antibodies while maintaining the formulations as a solution.

Taken together, Trillion Bio’s technology aims to convert long and expensive intravenous infusions of antibodies into a self-administered injections by concurrently reducing the dose requirement and increasing formulation concentrations.